Torpezil (Donepezil) Indication
Torpezil (donepezil) is indicated for the treatment of dementia of the Alzheimer's type, with demonstrated efficacy across mild, moderate, and severe stages of the disease 1.
FDA-Approved Indication
The FDA label is explicit and straightforward: donepezil hydrochloride is approved specifically for Alzheimer's disease dementia at all severity levels 1. This represents the only formal FDA-approved indication for this medication.
Evidence-Based Efficacy by Disease Stage
Alzheimer's Disease (Primary Indication)
- Mild to moderate AD: Donepezil shows statistically significant improvements in cognition (ADAS-cog scores) and global function (CIBIC-plus scores), though the average cognitive improvement does not consistently reach the clinically significant threshold of ≥4 points on ADAS-cog 2, 3
- Moderate to severe AD: The drug demonstrates continued benefit, with the 10 mg dose showing significant effects on cognition and global assessment 2, 3
- Severe AD: Efficacy has been established even in advanced disease stages 1
Off-Label Uses with Supporting Evidence
While not FDA-approved, clinical guidelines and research support donepezil use in:
Vascular dementia: Shows statistically significant treatment effects on cognition (ADAS-cog) and global function, with effect sizes smaller than those seen in Alzheimer's disease but still meaningful 2, 3. The 2008 American College of Physicians/American Academy of Family Physicians guideline acknowledges this evidence 2.
Lewy body dementia and Parkinson's disease dementia: Recent guidelines (2025) provide a strong recommendation for Lewy body dementia and conditional recommendation for Parkinson's disease dementia 4.
Not Indicated
Mild cognitive impairment (MCI): Donepezil is not effective for MCI. While it may temporarily reduce conversion rates to Alzheimer's disease in the short term, differences versus placebo disappear by 36 months, and no sustained benefit occurs 3.
Clinical Context
The evidence consistently shows that donepezil produces statistically significant but modest improvements in cognition and global function. A subset of patients achieves clinically meaningful improvement even when group averages do not reach clinical significance thresholds 2. The drug's primary value lies in symptomatic management rather than disease modification, with benefits maintained only during active treatment.
Common adverse effects are gastrointestinal (diarrhea, nausea, vomiting) and are dose-related, occurring more frequently with 10 mg versus 5 mg daily 2, 1.